Department of Hematology, the affiliated Huaian Hospital of Xuzhou Medical University, Huaian 223002, P.R. China.
J BUON. 2020 Mar-Apr;25(2):1042-1049.
To compare the efficacy and impact of GEMOX and GDP in the treatment of patients with non-Hodgkin's lymphoma (NHL).
A total of 68 patients with NHL admitted to the hospitals of the authors from February 2013 to April 2016 were equally distributed into the GEMOX Group (treated with Gemcitabine and Oxaliplatin) and the GDP Group (treated with Gemcitabine, Cisplatin, and Dexamethasone), with cycle repetition every 3 weeks. The efficacy was analyzed every two weeks. The side effects were analyzed once a week. Comparison of survival was performed using Kaplan-Meier method and log-rank test and Cox univariate and multivariate regression analyses.
Efficacy in the two groups was not statistically different (p>0.05). The incidence of III-IV grade of nausea and vomiting in the GDP Group was higher than in the GEMOX Group (p<0.05). The overall incidence decreased hemoglobin, nausea and vomiting, and renal dysfunction of the GDP Group was also higher than in the GEMOX Group (p<0.05). Analysis by multivariate Cox model found that the clinical classification and the grade of malignancy were independent prognostic factors (p<0.05). The odds ratio (OR) values of the clinical classification in the GEMOX Group and the GDP Group were 2.874 and 24.074, respectively. The OR values of the grade of malignancy in the GEMOX Group and the GDP Group were 14.034 and 6.873, respectively.
Both the GEMOX regimen and the GDP regimen had good short-term efficacy on NHL patients, but the GEMOX regimen is to be preferred since as it had fewer side effects than the GDP regimen.
比较吉西他滨联合奥沙利铂（GEMOX）与吉西他滨联合顺铂、地塞米松（GDP）方案治疗非霍奇金淋巴瘤（NHL）的疗效和影响。
选取 2013 年 2 月至 2016 年 4 月在我院治疗的 NHL 患者 68 例，随机分为 GEMOX 组（吉西他滨联合奥沙利铂）和 GDP 组（吉西他滨联合顺铂、地塞米松），每组 34 例。每 3 周重复一个周期，每两周评价一次疗效，每周评价一次不良反应。采用 Kaplan-Meier 法和 log-rank 检验进行生存比较，采用 Cox 单因素和多因素回归分析。
两组疗效差异无统计学意义（P＞0.05）。GDP 组 III-IV 级恶心呕吐发生率高于 GEMOX 组（P＜0.05）。两组均出现不同程度的血红蛋白降低、恶心呕吐和肾功能不全，且 GDP 组发生率高于 GEMOX 组（P＜0.05）。多因素 Cox 模型分析发现，临床分期和恶性程度分级是独立预后因素（P＜0.05）。GEMOX 组和 GDP 组临床分期的优势比（OR）值分别为 2.874 和 24.074，恶性程度分级的 OR 值分别为 14.034 和 6.873。
GEMOX 方案和 GDP 方案治疗 NHL 患者均有较好的近期疗效，但 GEMOX 方案不良反应更少，优于 GDP 方案。
